Moreover, the burst-terms analysis indicated that identifying the clinical significance of MCT1 inhibitors as anti-cancer or immunosuppressive drugs and the possibility of drug-resistance formation are the frontier issues in this field. The gene discussed is SLC16A1; the disease is cancer.